DANAHER CORP, headquartered in the United States, reported first-quarter profit results that exceeded Wall Street expectations on Tuesday. The life sciences firm saw its shares climb 2% in premarket trading following the announcement, which highlighted a surge in demand for bioprocessing tools used in drug manufacturing. The results suggest improving market conditions as pharmaceutical companies increase spending on drug discovery and development.
Danaher Tops Q1 Profit Estimates on Bioprocessing Growth
Danaher reported quarterly earnings of $2.06 per share, beating analyst estimates. Growth in bioprocessing tools offset weaker demand for diagnostic tests.
Xurve View
洞察:
Xurve View
The Washington, D.C.-based company reported adjusted earnings of $2.06 per share for the quarter ended March 27, surpassing the average analyst estimate of $1.94 per share. Total quarterly revenue reached $5.95 billion, falling slightly short of the $6 billion anticipated by analysts. CEO Rainer Blair attributed the performance to a steady recovery within the company's core segments.











